During the PHE, Medicare covered all costs for monoclonal antibody treatments and oral antiviral treatments to treat your COVID infection.
The Consolidated Appropriations Act of 2023 extended coverage for oral antiviral medications through December 31, 2024. All other treatments will require cost-sharing after the PHE ends. Please know that not all COVID-related medications will necessarily be covered by your Part D plan.